646 related articles for article (PubMed ID: 29873531)
1. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
[TBL] [Abstract][Full Text] [Related]
2. New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy.
Safdar MH; Hussain Z; Abourehab MAS; Hasan H; Afzal S; Thu HE
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1967-1980. PubMed ID: 29082766
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
4. "Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy.
Kemp JA; Shim MS; Heo CY; Kwon YJ
Adv Drug Deliv Rev; 2016 Mar; 98():3-18. PubMed ID: 26546465
[TBL] [Abstract][Full Text] [Related]
5. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
6. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
He Q; Shi J
Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
[TBL] [Abstract][Full Text] [Related]
7. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
[TBL] [Abstract][Full Text] [Related]
8. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy.
Shen S; Liu M; Li T; Lin S; Mo R
Biomater Sci; 2017 Jul; 5(8):1367-1381. PubMed ID: 28664207
[TBL] [Abstract][Full Text] [Related]
10. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
12. Programmable nanomedicine: synergistic and sequential drug delivery systems.
Pacardo DB; Ligler FS; Gu Z
Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
[TBL] [Abstract][Full Text] [Related]
13. Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies.
Jang B; Kwon H; Katila P; Lee SJ; Lee H
Adv Drug Deliv Rev; 2016 Mar; 98():113-33. PubMed ID: 26654747
[TBL] [Abstract][Full Text] [Related]
14. Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery.
Wang Z; Chen J; Little N; Lu J
Acta Biomater; 2020 Jul; 111():20-28. PubMed ID: 32454086
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes.
Anwar DM; El-Sayed M; Reda A; Fang JY; Khattab SN; Elzoghby AO
Expert Opin Drug Deliv; 2021 Nov; 18(11):1609-1625. PubMed ID: 34254868
[No Abstract] [Full Text] [Related]
16. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
19. The potential of multi-compound nanoparticles to bypass drug resistance in cancer.
Da Silva CG; Peters GJ; Ossendorp F; Cruz LJ
Cancer Chemother Pharmacol; 2017 Nov; 80(5):881-894. PubMed ID: 28887666
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond.
Iqbal J; Abbasi BA; Ahmad R; Mahmood T; Ali B; Khalil AT; Kanwal S; Shah SA; Alam MM; Badshah H; Munir A
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9449-9470. PubMed ID: 30219952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
